Treatment with Bimatoprost for Exophthalmos in Patients with Inactive Thyroid-associated Ophthalmopathy

Overview

Journal Clin Ophthalmol

Publisher Dove Medical Press

Specialty Ophthalmology

Date 2018 Dec 21

PMID 30568419

Citations 1

Authors

Tomoaki Higashiyama

Masahito Ohji

Affiliations

Soon will be listed here.

Abstract

Purpose: This study was performed to observe changes prospectively in exophthalmos and orbital fat in patients with inactive thyroid-associated ophthalmopathy (TAO) treated with bimatoprost.

Methods: In this 12-month single-treatment pilot observational study, 13 patients with inactive-phase TAO were administered bimatoprost to treat exophthalmos due to TAO. Exophthalmos values and orbital tissue volumes were measured on MRI by technicians in a masked fashion.

Results: Nine orbits of nine patients (eight women, one man) were treated with bimatoprost for 12 months. Mean exophthalmos values before and after treatment were 21.7±2.2 and 21.7±2.0 mm, respectively. The mean value after 12 months of treatment was not significantly different from before treatment (=0.82). Mean orbital fat volume before and after 12 months of treatment was 17.2±2.5 and 17.0±3.0 cm, respectively. The corresponding total extraocular muscle volume was 4.0±0.7 and 3.8±0.9 cm, respectively. Mean volume in each tissue type after 12 months of treatment was not significantly different from before treatment (orbital fat, =0.70; extraocular muscles, =0.32).

Conclusion: Topical bimatoprost treatment did not reduce exophthalmos or orbital fat in this cohort of patients with inactive TAO.

Citing Articles

From Eye Care to Hair Growth: Bimatoprost.

Zeppieri M, Gagliano C, Spadea L, Salati C, Chukwuyem E, Enaholo E Pharmaceuticals (Basel). 2024; 17(5).

PMID: 38794131 PMC: 11124470. DOI: 10.3390/ph17050561.

References

Tian S, Nishida Y, Isberg B, Lennerstrand G . MRI measurements of normal extraocular muscles and other orbital structures. Graefes Arch Clin Exp Ophthalmol. 2000; 238(5):393-404. DOI: 10.1007/s004170050370. View

Murakami Y, Kanamoto T, Tuboi T, Maeda T, Inoue Y . Evaluation of extraocular muscle enlargement in dysthyroid ophthalmopathy. Jpn J Ophthalmol. 2002; 45(6):622-7. DOI: 10.1016/s0021-5155(01)00407-5. View

Nishida Y, Tian S, Isberg B, Tallstedt L, Lennerstrand G . MRI measurements of orbital tissues in dysthyroid ophthalmopathy. Graefes Arch Clin Exp Ophthalmol. 2002; 239(11):824-31. DOI: 10.1007/s004170100352. View

Koumas L, Smith T, Phipps R . Fibroblast subsets in the human orbit: Thy-1+ and Thy-1- subpopulations exhibit distinct phenotypes. Eur J Immunol. 2002; 32(2):477-85. DOI: 10.1002/1521-4141(200202)32:2<477::AID-IMMU477>3.0.CO;2-U. View

Han R, Tsui S, Smith T . Up-regulation of prostaglandin E2 synthesis by interleukin-1beta in human orbital fibroblasts involves coordinate induction of prostaglandin-endoperoxide H synthase-2 and glutathione-dependent prostaglandin E2 synthase expression. J Biol Chem. 2002; 277(19):16355-64. DOI: 10.1074/jbc.M111246200. View

Hatton M, Rubin P . The pathophysiology of thyroid-associated ophthalmopathy. Ophthalmol Clin North Am. 2002; 15(1):113-9. DOI: 10.1016/s0896-1549(01)00004-9. View

Nishida Y, Tian S, Isberg B, Hayashi O, Tallstedt L, Lennerstrand G . Significance of orbital fatty tissue for exophthalmos in thyroid-associated ophthalmopathy. Graefes Arch Clin Exp Ophthalmol. 2002; 240(7):515-20. DOI: 10.1007/s00417-002-0498-3. View

Ohtsuka K, Sato A, Kawaguchi S, Hashimoto M, Suzuki Y . Effect of high-dose intravenous steroid pulse therapy followed by 3-month oral steroid therapy for Graves' ophthalmopathy. Jpn J Ophthalmol. 2002; 46(5):563-7. DOI: 10.1016/s0021-5155(02)00544-0. View

Prummel M, Bakker A, Wiersinga W, Baldeschi L, Mourits M, Kendall-Taylor P . Multi-center study on the characteristics and treatment strategies of patients with Graves' orbitopathy: the first European Group on Graves' Orbitopathy experience. Eur J Endocrinol. 2003; 148(5):491-5. DOI: 10.1530/eje.0.1480491. View

10.

El-Kaissi S, Frauman A, Wall J . Thyroid-associated ophthalmopathy: a practical guide to classification, natural history and management. Intern Med J. 2004; 34(8):482-91. DOI: 10.1111/j.1445-5994.2004.00662.x. View

11.

Arner P . Human fat cell lipolysis: biochemistry, regulation and clinical role. Best Pract Res Clin Endocrinol Metab. 2005; 19(4):471-82. DOI: 10.1016/j.beem.2005.07.004. View

12.

Liu L, Clipstone N . Prostaglandin F2alpha inhibits adipocyte differentiation via a G alpha q-calcium-calcineurin-dependent signaling pathway. J Cell Biochem. 2006; 100(1):161-73. DOI: 10.1002/jcb.21044. View

13.

Lennerstrand G, Tian S, Isberg B, Landau Hogbeck I, Bolzani R, Tallstedt L . Magnetic resonance imaging and ultrasound measurements of extraocular muscles in thyroid-associated ophthalmopathy at different stages of the disease. Acta Ophthalmol Scand. 2007; 85(2):192-201. DOI: 10.1111/j.1600-0420.2006.00807.x. View

14.

Richter D, Stoff A, Olivari N . Transpalpebral decompression of endocrine ophthalmopathy by intraorbital fat removal (Olivari technique): experience and progression after more than 3000 operations over 20 years. Plast Reconstr Surg. 2007; 120(1):109-123. DOI: 10.1097/01.prs.0000263655.47148.9e. View

15.

Bartalena L, Baldeschi L, Dickinson A, Eckstein A, Kendall-Taylor P, Marcocci C . Consensus statement of the European Group on Graves' orbitopathy (EUGOGO) on management of GO. Eur J Endocrinol. 2008; 158(3):273-85. DOI: 10.1530/EJE-07-0666. View

16.

Lehmann G, Feldon S, Smith T, Phipps R . Immune mechanisms in thyroid eye disease. Thyroid. 2008; 18(9):959-65. PMC: 2795569. DOI: 10.1089/thy.2007.0407. View

17.

Yang H, Park K, Kim T, Kim D . Deepening of eyelid superior sulcus during topical travoprost treatment. Jpn J Ophthalmol. 2009; 53(2):176-179. DOI: 10.1007/s10384-008-0623-x. View

18.

Bahn R . Graves' ophthalmopathy. N Engl J Med. 2010; 362(8):726-38. PMC: 3902010. DOI: 10.1056/NEJMra0905750. View

19.

Jayaprakasam A, Ghazi-Nouri S . Periorbital fat atrophy - an unfamiliar side effect of prostaglandin analogues. Orbit. 2010; 29(6):357-9. DOI: 10.3109/01676830.2010.527028. View

20.

Inoue K, Shiokawa M, Wakakura M, Tomita G . Deepening of the upper eyelid sulcus caused by 5 types of prostaglandin analogs. J Glaucoma. 2012; 22(8):626-31. DOI: 10.1097/IJG.0b013e31824d8d7c. View